Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oncology

Modern Treatments: Immunotherapy and Precision Medicine

At a Glance

The standard first-line treatment for advanced cholangiocarcinoma now combines chemotherapy with immunotherapy, such as durvalumab. Additionally, genomic testing or liquid biopsies can identify specific DNA mutations, allowing doctors to use targeted therapies tailored to your cancer's genetics.

For patients with advanced or unresectable cholangiocarcinoma (CCA), treatment has moved far beyond a “one-size-fits-all” approach. In recent years, the integration of immunotherapy and precision medicine has fundamentally changed the standard of care, offering more personalized pathways based on the specific biology of your tumor.

The First-Line Standard: Adding Immunotherapy

The current “gold standard” for the initial treatment of advanced CCA is a combination of chemotherapy and immunotherapy [1][2].

  • The TOPAZ-1 Breakthrough: A landmark clinical trial called TOPAZ-1 proved that adding the immunotherapy drug durvalumab to the traditional chemotherapy duo of gemcitabine and cisplatin significantly improved survival compared to chemotherapy alone [1][3].
  • How it works: While chemotherapy attacks rapidly dividing cancer cells, immunotherapy helps your body’s own immune system recognize and destroy the cancer [4].
  • Pembrolizumab: In some cases, a similar immunotherapy drug called pembrolizumab may also be used in combination with chemotherapy for previously untreated advanced bile duct cancer [5].

Precision Medicine: Matching the Treatment to the Mutation

If the first-line treatment stops working, or sometimes even before it starts, your doctors will look for “actionable” genetic mutations [6]. This is done through genomic profiling, which is a way of mapping the unique DNA errors in your cancer cells [7].

Several targeted therapies are now FDA-approved for patients who have specific alterations:

  • FGFR2 Fusions: These are common in the intrahepatic (inside the liver) type of CCA. Drugs like pemigatinib and futibatinib are specifically designed to block the FGFR2 pathway and stop tumor growth [8][9].
  • IDH1 Mutations: For patients with an IDH1 mutation, a drug called ivosidenib has been shown to slow disease progression [10][11].
  • BRAF V600E: If your tumor has this specific mutation, a combination of dabrafenib and trametinib may be used [11].
  • HER2 Alterations: If your cancer overexpresses the HER2 protein, your team may consider HER2-targeted agents like zanidatamab [12][13].

The Role of Liquid Biopsy (ctDNA)

To find these mutations, doctors usually need a piece of the tumor (a tissue biopsy). However, bile duct tumors can be hard to reach, or the sample might be too small for full testing [14].

  • What is it? A liquid biopsy is a blood test that looks for circulating tumor DNA (ctDNA)—tiny fragments of DNA that the cancer sheds into your bloodstream [15][16].
  • When to use it: If a traditional biopsy isn’t possible, a liquid biopsy can provide the necessary molecular information to select a targeted therapy [17][18]. It can also be used to monitor how your cancer is responding to treatment in real-time [14].

Looking Forward

Precision medicine has transformed advanced CCA from a disease with limited options into one where treatment is increasingly guided by your tumor’s “genetic fingerprint” [6]. Ensuring you have had comprehensive molecular testing—whether through tissue or blood—is the most critical step in accessing these modern, targeted therapies [7].

Common questions in this guide

What is the first-line treatment for advanced cholangiocarcinoma?
The current gold standard for initial treatment is a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug like durvalumab. This combination has been shown to improve survival compared to using chemotherapy alone.
How does immunotherapy work for bile duct cancer?
While traditional chemotherapy directly attacks rapidly dividing cancer cells, immunotherapy works differently. It helps your body's own immune system better recognize, target, and destroy the cancer cells.
What is targeted therapy for cholangiocarcinoma?
Targeted therapies are medications designed to attack specific genetic mutations found in your cancer cells. For example, there are FDA-approved drugs for bile duct tumors that have FGFR2 fusions, IDH1 mutations, BRAF V600E mutations, or HER2 alterations.
Why might my doctor order a liquid biopsy (ctDNA test)?
A liquid biopsy is a simple blood test that looks for tiny fragments of tumor DNA floating in your bloodstream. It is used when a traditional tissue biopsy is too difficult to get or too small, helping doctors find genetic mutations to guide your treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for the combination of durvalumab with gemcitabine and cisplatin as my first-line treatment?
  2. 2.Has my tumor been tested for actionable mutations like FGFR2, IDH1, BRAF, or HER2?
  3. 3.If my tissue sample was too small for testing, can we use a liquid biopsy (ctDNA) to look for these mutations?
  4. 4.If my cancer progresses on the first-line treatment, which specific targeted therapies are available for my genetic profile?
  5. 5.What are the potential side effects of adding immunotherapy to my chemotherapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Durvalumab: A Review in Advanced Biliary Tract Cancer.

    Fung S, Syed YY

    Targeted oncology 2023; (18(6)):965-972 doi:10.1007/s11523-023-01007-y.

    PMID: 37943483
  2. 2

    Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.

    Rimini M, Fornaro L, Rizzato MD, et al.

    European journal of cancer (Oxford, England : 1990) 2024; (208()):114199 doi:10.1016/j.ejca.2024.114199.

    PMID: 39002348
  3. 3

    Exploring the impact of first-line durvalumab plus chemotherapy on advanced biliary tract cancer: a systematic review and meta-analysis.

    Reimann P, Schneider EM, Djanani A, et al.

    The oncologist 2025; (30(9)) doi:10.1093/oncolo/oyaf224.

    PMID: 40700609
  4. 4

    Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.

    Yang X, Lian B, Zhang N, et al.

    BMC medicine 2024; (22(1)):42 doi:10.1186/s12916-024-03257-7.

    PMID: 38281914
  5. 5

    Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kelley RK, Ueno M, Yoo C, et al.

    Lancet (London, England) 2023; (401(10391)):1853-1865 doi:10.1016/S0140-6736(23)00727-4.

    PMID: 37075781
  6. 6

    Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms.

    Choucair K, Chamseddine S, Azmi A, Philip PA

    Frontiers in oncology 2026; (16()):1769447 doi:10.3389/fonc.2026.1769447.

    PMID: 41756323
  7. 7

    Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes.

    Pudlarz T, Turpin A, Tissera NS, et al.

    JHEP reports : innovation in hepatology 2025; (7(11)):101550 doi:10.1016/j.jhepr.2025.101550.

    PMID: 41078701
  8. 8

    Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

    Goyal L, Meric-Bernstam F, Hollebecque A, et al.

    The New England journal of medicine 2023; (388(3)):228-239 doi:10.1056/NEJMoa2206834.

    PMID: 36652354
  9. 9

    Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.

    Rengan AK, Denlinger CS

    Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(5)):430-435 doi:10.6004/jnccn.2021.7121.

    PMID: 35378504
  10. 10

    Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

    Zhu AX, Macarulla T, Javle MM, et al.

    JAMA oncology 2021; (7(11)):1669-1677 doi:10.1001/jamaoncol.2021.3836.

    PMID: 34554208
  11. 11

    Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.

    Heumann P, Albert A, Gülow K, et al.

    Cancers 2024; (16(9)) doi:10.3390/cancers16091690.

    PMID: 38730642
  12. 12

    Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers.

    Smolenschi C, Blanc JF, Lancry A, et al.

    European journal of cancer (Oxford, England : 1990) 2025; (222()):115432 doi:10.1016/j.ejca.2025.115432.

    PMID: 40319675
  13. 13

    How to incorporate new agents into precise medicine for cholangiocarcinoma?

    Li Y, Kang J, Zhang X

    American journal of cancer research 2024; (14(5)):2570-2583 doi:10.62347/NFDL2398.

    PMID: 38859865
  14. 14

    Circulating tumor DNA: Where are we now? A mini review of the literature.

    Galarza Fortuna GM, Dvir K

    World journal of clinical oncology 2020; (11(9)):723-731 doi:10.5306/wjco.v11.i9.723.

    PMID: 33033694
  15. 15

    The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments.

    Di Capua D, Bracken-Clarke D, Ronan K, et al.

    Cancers 2021; (13(16)) doi:10.3390/cancers13163923.

    PMID: 34439082
  16. 16

    Clinical implementation and current advancement of blood liquid biopsy in cancer.

    Watanabe K, Nakamura Y, Low SK

    Journal of human genetics 2021; (66(9)):909-926 doi:10.1038/s10038-021-00939-5.

    PMID: 34088974
  17. 17

    Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.

    van 't Erve I, Medina JE, Leal A, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(5)):899-909 doi:10.1158/1078-0432.CCR-22-2538.

    PMID: 36534496
  18. 18

    [Progression and application of circulating tumor DNA in lymphoma].

    Huang DZ, Zhang X, Rao J

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(9)):878-882 doi:10.3760/cma.j.cn121090-20240528-00197.

    PMID: 39414617

This page provides educational information about advanced cholangiocarcinoma treatments. Always consult your medical oncologist to determine the best therapy and genetic testing approach for your specific tumor profile.

Get notified when new evidence is published on Cholangiocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.